35 related articles for article (PubMed ID: 12552998)
1. Preferential induction of apoptosis for primary human leukemic stem cells.
Guzman ML; Swiderski CF; Howard DS; Grimes BA; Rossi RM; Szilvassy SJ; Jordan CT
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16220-5. PubMed ID: 12451177
[TBL] [Abstract][Full Text] [Related]
2. Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens.
Ren Y; Gallucci JC; Li X; Chen L; Yu J; Kinghorn AD
J Nat Prod; 2018 Mar; 81(3):554-561. PubMed ID: 29350920
[TBL] [Abstract][Full Text] [Related]
3. Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies.
Sztiller-Sikorska M; Czyz M
Pharmaceuticals (Basel); 2020 Aug; 13(8):. PubMed ID: 32823992
[TBL] [Abstract][Full Text] [Related]
4. Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo.
Nakabayashi H; Shimizu K
BMC Cancer; 2012 Oct; 12():453. PubMed ID: 23039130
[TBL] [Abstract][Full Text] [Related]
5. Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Matsunaga T; Wada Y; Endo S; Soda M; El-Kabbani O; Hara A
Front Pharmacol; 2012; 3():5. PubMed ID: 22319498
[TBL] [Abstract][Full Text] [Related]
6. Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells.
Czyz M; Lesiak-Mieczkowska K; Koprowska K; Szulawska-Mroczek A; Wozniak M
Br J Pharmacol; 2010 Jul; 160(5):1144-57. PubMed ID: 20590608
[TBL] [Abstract][Full Text] [Related]
7. Targeting proteasome inhibition in hematologic malignancies.
Hideshima T; Richardson PG; Anderson KC
Rev Clin Exp Hematol; 2003 Jun; 7(2):191-204. PubMed ID: 14763162
[TBL] [Abstract][Full Text] [Related]
8. The proteasome: a novel target for cancer chemotherapy.
Almond JB; Cohen GM
Leukemia; 2002 Apr; 16(4):433-43. PubMed ID: 11960320
[TBL] [Abstract][Full Text] [Related]
9. Bis(2-hydroxybenzylidene)acetone, a potent inducer of the phase 2 response, causes apoptosis in mouse leukemia cells through a p53-independent, caspase-mediated pathway.
Dinkova-Kostova AT; Cory AH; Bozak RE; Hicks RJ; Cory JG
Cancer Lett; 2007 Jan; 245(1-2):341-9. PubMed ID: 16517063
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of apoptosis responses in p53-deficient L1210 cells by compounds directed at blocking NFkappaB activation.
Cory AH; Cory JG
Anticancer Res; 2001; 21(6A):3807-11. PubMed ID: 11911251
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in p53-deficient L1210 cells by an I-kappa-B-alpha-inhibitor (Bay 11-7085) via a NF-kappa-B-independent mechanism.
Cory AH; Cory JG
Adv Enzyme Regul; 2005; 45():85-93. PubMed ID: 16129475
[TBL] [Abstract][Full Text] [Related]
12. Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells.
Somerville L; Cory JG
Anticancer Res; 2000; 20(5B):3347-55. PubMed ID: 11131634
[TBL] [Abstract][Full Text] [Related]
13. Proteasome-dependent regulation of p21WAF1/CIP1 expression.
Blagosklonny MV; Wu GS; Omura S; el-Deiry WS
Biochem Biophys Res Commun; 1996 Oct; 227(2):564-9. PubMed ID: 8878553
[TBL] [Abstract][Full Text] [Related]
14. Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells.
Cory AH; Cory JG
Anticancer Res; 2002; 22(6C):3805-9. PubMed ID: 12552998
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
